RESUMEN
ObjectiveTo conduct a meta-analysis of the articles on the effect of silibinin on aminotransferases in patients with nonalcoholic fatty liver disease (NAFLD), and to investigate the liver-protecting effect of silibinin in patients with NAFLD. MethodsCNKI, Wanfang Data, VIP, SinoMed, PubMed, MEDLINE, Embase, and ScienceDirect were searched for randomized controlled trials (RCTs) on the treatment of NAFLD patients with silibinin, The articles were screened according to inclusion and exclusion criteria, and then quality assessment and data extraction were performed. RevMan 5.3 was used to perform the meta-analysis. ResultsA total of 8 articles with 665 patients were included. After 8 weeks to 3 months of silibinin treatment, there were significant reductions in the serum levels of alanine aminotransferase (ALT) (weighted mean difference ［WMD］=-11.60, 95% confidence interval ［CI］: -18.68 to -4.51, P=0.001) and aspartate aminotransferase (AST) (WMD=-11.56, 95% CI: -16.93 to -6.18, P＜0.001). Conclusion Silibinin can significantly reduce the serum levels of ALT and AST in patients with NAFLD.
RESUMEN
Hepatorenal syndrome is a serious complication of decompensated cirrhosis and has high short -term mortality.There still lacks effective medical treatment at present.Although some drugs are effective, but their effects reported in the literature were different due to a lack of uniform diagnostic criteria.This article introduces the changes in the diagnostic criteria for hepatorenal syndrome and points out that uniform diagnostic criteria will become the basis for clinical research on hepatorenal syndrome and may also help clinicians to understand this serious complication of liver cirrhosis.